Cited by 67Glioma Diagnosis and TreatmentOvarian cancer diagnosis and treatmentAcute Myeloid Leukemia Research

Is Visible Aminolevulinic Acid-Induced Fluorescence an Independent Biomarker for Prognosis in Histologically Confirmed (World Health Organization 2016) Low-Grade Gliomas?

Open access
Jaber, Mohammed, Ewelt, Christian, Wölfer, Johannes, Brokinkel, Benjamin, Thomas, Christian, Hasselblatt, Martin, Grauer, Oliver, Stummer, Walter·2019·Neurosurgery

Abstract

BACKGROUND: Approximately 20% of low-grade gliomas (LGG) display visible protoporphyrin fluorescence during surgery after 5-aminolevulinic acid (5-ALA) administration. OBJECTIVE: To determine if fluorescence represents a prognostic marker in LGG. METHODS: Seventy-four consecutive patients with LGG (World Health Organization 2016) were operated on with 5-ALA. Fluorescent tissue was specifically biopsied. Tumor size, age, Karnofsky index, contrast-enhancement, fluorescence, and molecular factors (IDH1/IDH2-mutations, Ki67/MIB1 Index, 1p19q codeletions, ATRX, EGFR, p53 expression, and O 6 -methylguanine DNA methyltransferase promotor methylation), were related to progression-free survival (PFS), malignant transformation-free survival (MTFS) and overall survival (OS). RESULTS: Sixteen of seventy-four LGGs (21.6%) fluoresced. Fluorescence was partially related to weak enhancement on magnetic resonance imaging and increased (positron emission tomography)PET-FET uptake, but not to Karnofsky Performance Score, tumor size, or age. Regarding molecular markers, only EGFR expression differed marginally (fluorescing vs nonfluorescing: 19% vs 5%; P = .057). Median follow-up was 46.4 mo (95% confidence interval [CI]: 41.8-51.1). PFS, MTFS, and OS were shorter in fluorescing tumors (PFS: median 9.8 mo, 95% CI: 1.00-27.7 vs 45.8, 31.9-59.7, MTFS: 43.0 [27.5-58.5] vs 64.6 [57.7-71.5], median not reached, P = .015; OS: 51.6, [34.8-68.3] vs [68.2, 62.7-73.8], P = .002). IDH mutations significantly predicted PFS, MTFS, and OS. In multivariate analysis IDH status and fluorescence both independently predicted MTFS and OS. PFS was not independently predicted by fluorescence. CONCLUSION: This is the first report investigating the role of ALA-induced fluorescence in histologically confirmed LGG. Fluorescence appeared to be a marker for inherent malignant transformation and OS, independently of known prognostic markers. Fluorescence in LGG might be taken into account when deciding on adjuvant therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuros/nyy365

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Comparison between fluorescing and non-fluorescing low-grade gliomas revealed significant differences in gadolinium enhancement, tumor cell proliferation, and 18F-FET PET uptake.

    “A comparison between fluorescing and non-fluorescing low-grade gliomas revealed significant differences in gadolinium enhancement, tumor cell proliferation, and 18F-fluoroethyl-l-tyrosine (18F-FET) PET uptake, suggesting a distinction in tumor cell biology and tumor microenvironment [52,53].”

    From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [52]

    The Results (Patient and Imaging Characteristics; page not supplied) report significant differences between fluorescing and non-fluorescing low-grade gliomas in MRI contrast enhancement (P = .001) and PET uptake (P = .009). But the same section says the median MIB proliferation index did not differ between the groups, contrary to the claimed difference in tumor cell proliferation. (LLM, conf=0.91)

    Experimental — accuracy not yet measured
  • The association between positive PpIX fluorescence and gadolinium contrast enhancement highlights the importance of the blood-brain barrier in PpIX fluorescence positivity.

    “Particularly, the association between positive PpIX fluorescence and gadolinium contrast enhancement highlights the importance of the blood-brain barrier (BBB) in PpIX fluorescence positivity.”
  • Patients with low-grade gliomas that show PpIX fluorescence often have poor prognoses compared to patients whose tumors do not fluoresce.

    “Nevertheless, patients with low-grade gliomas that do show PpIX fluorescence often have poor prognoses compared to patients whose tumors do not fluoresce, prompting the possible use of PpIX fluorescence as a prognostic marker for low-grade gliomas [51,52].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 61 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Valdés PA, Bekelis K, Harris BT etal. 5-Aminolevulinic acidinduced protoporphyrin IX fluorescence in meningioma: qualitative and quantitative measurements in vivo. Neurosurgery. 2014; 10(Suppl 1): 74- 82. 23887194 PMC4237006
  2. Eckel-Passow JE, Lachance DH, Molinaro AM, et al Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015; 372(26): 2499- 2508. 26061753 PMC4489704

Cited by

Sorted by citations

Authors
Jaber, M., Ewelt, C., Wölfer, J., Brokinkel, B., Thomas, C., Hasselblatt, M., Grauer, O., & Stummer, W.
Affiliations
University Hospital Münster (DE)
Corresponding author
Stummer, Walter
Venue
Neurosurgery
Published
2018-08-09
Volume
84
Issue
6
Pages
1214-1224
ISSN
  • 0148-396X (ISSN-L)
  • 1524-4040
OpenAlex
W2886579043
Cited by
66
References
61
Citations by year
2026: 1 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 18 · 2021: 15 · 2020: 7 · 2019: 10 · 2018: 1
FWCI
4.68
Type
journal article
Language
en
Open access
Locations
  • Neurosurgery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
low-grade glioma, 5-aminolevulinic acid fluorescence, prognostic factors, IDH mutation, malignant transformation, progression-free survival, overall survival, EGFR expression, 1p/19q codeletion, ATRX, p53, MGMT promoter methylation, MRI contrast enhancement
MeSH terms
Adult, Aminolevulinic Acid, Biopsy, Brain Neoplasms, Female, Fluorescence, Glioma, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Prognosis, Protoporphyrins, Biomarkers, Karnofsky Performance Status, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review